Baxter ROE 2012-2026 | BAX
Current and historical return on equity (ROE) values for Baxter (BAX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Baxter ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-03-31 | $-1.10B | $3.63B | -30.28% |
| 2025-12-31 | $-0.96B | $5.39B | -17.75% |
| 2025-09-30 | $-0.34B | $7.15B | -4.77% |
| 2025-06-30 | $-0.16B | $7.33B | -2.12% |
| 2025-03-31 | $-0.56B | $7.43B | -7.53% |
| 2024-12-31 | $-0.65B | $7.73B | -8.40% |
| 2024-09-30 | $0.11B | $8.09B | 1.34% |
| 2024-06-30 | $2.48B | $8.14B | 30.40% |
| 2024-03-31 | $2.65B | $7.63B | 34.74% |
| 2023-12-31 | $2.66B | $7.05B | 37.67% |
| 2023-09-30 | $2.59B | $6.41B | 40.45% |
| 2023-06-30 | $-2.85B | $5.76B | -49.52% |
| 2023-03-31 | $-2.46B | $6.58B | -37.39% |
| 2022-12-31 | $-2.43B | $7.37B | -32.99% |
| 2022-09-30 | $-2.38B | $8.18B | -29.04% |
| 2022-06-30 | $1.01B | $8.99B | 11.25% |
| 2022-03-31 | $1.06B | $8.90B | 11.88% |
| 2021-12-31 | $1.28B | $8.74B | 14.69% |
| 2021-09-30 | $1.21B | $8.64B | 14.05% |
| 2021-06-30 | $1.12B | $8.59B | 13.04% |
| 2021-03-31 | $1.07B | $8.50B | 12.57% |
| 2020-12-31 | $1.10B | $8.31B | 13.27% |
| 2020-09-30 | $0.91B | $8.10B | 11.25% |
| 2020-06-30 | $0.92B | $7.86B | 11.76% |
| 2020-03-31 | $0.99B | $7.77B | 12.75% |
| 2019-12-31 | $1.00B | $7.76B | 12.90% |
| 2019-09-30 | $1.32B | $7.75B | 17.04% |
| 2019-06-30 | $1.47B | $8.12B | 18.09% |
| 2019-03-31 | $1.50B | $8.38B | 17.89% |
| 2018-12-31 | $1.55B | $8.74B | 17.70% |
| 2018-09-30 | $1.06B | $9.05B | 11.76% |
| 2018-06-30 | $0.80B | $9.13B | 8.73% |
| 2018-03-31 | $0.72B | $9.21B | 7.81% |
| 2017-12-31 | $0.60B | $9.10B | 6.61% |
| 2017-09-30 | $1.03B | $8.90B | 11.59% |
| 2017-06-30 | $0.91B | $8.70B | 10.46% |
| 2017-03-31 | $1.86B | $8.53B | 21.76% |
| 2016-12-31 | $4.97B | $8.62B | 57.61% |
| 2016-09-30 | $4.93B | $8.77B | 56.21% |
| 2016-06-30 | $4.80B | $8.56B | 56.05% |
| 2016-03-31 | $3.92B | $8.44B | 46.43% |
| 2015-12-31 | $0.97B | $8.01B | 12.09% |
| 2015-09-30 | $1.72B | $7.83B | 21.92% |
| 2015-06-30 | $2.18B | $7.97B | 27.38% |
| 2015-03-31 | $2.37B | $8.14B | 29.13% |
| 2014-12-31 | $2.50B | $8.49B | 29.41% |
| 2014-09-30 | $1.87B | $8.57B | 21.81% |
| 2014-06-30 | $1.95B | $8.40B | 23.16% |
| 2014-03-31 | $2.02B | $8.06B | 25.01% |
| 2013-12-31 | $2.01B | $7.64B | 26.35% |
| 2013-09-30 | $2.18B | $7.26B | 30.03% |
| 2013-06-30 | $2.22B | $7.12B | 31.16% |
| 2013-03-31 | $2.29B | $6.95B | 32.97% |
| 2012-12-31 | $2.33B | $6.94B | 33.54% |
| 2012-09-30 | $2.30B | $6.90B | 33.27% |
| 2012-06-30 | $2.29B | $6.90B | 33.17% |
| 2012-03-31 | $2.24B | $7.06B | 31.77% |
| 2011-12-31 | $2.22B | $7.06B | 31.51% |
| 2011-09-30 | $2.18B | $7.05B | 30.98% |
| 2011-06-30 | $2.13B | $6.94B | 30.72% |
| 2011-03-31 | $2.05B | $6.67B | 30.80% |
| 2010-12-31 | $1.42B | $6.59B | 21.55% |
| 2010-09-30 | $1.57B | $6.74B | 23.27% |
| 2010-06-30 | $1.57B | $6.88B | 22.87% |
| 2010-03-31 | $1.63B | $7.04B | 23.09% |
| 2009-12-31 | $2.21B | $6.92B | 31.88% |
| 2009-09-30 | $2.20B | $6.63B | 33.20% |
| 2009-06-30 | $2.14B | $6.57B | 32.63% |
| 2009-03-31 | $2.10B | $6.68B | 31.44% |
| 2008-12-31 | $2.01B | $6.89B | 29.22% |
| 2008-09-30 | $1.92B | $7.05B | 27.29% |
| 2008-06-30 | $1.85B | $6.86B | 26.93% |
| 2008-03-31 | $1.73B | $6.72B | 25.78% |
| 2007-12-31 | $1.71B | $6.63B | 25.77% |
| 2007-09-30 | $1.66B | $6.46B | 25.70% |
| 2007-06-30 | $1.64B | $6.48B | 25.33% |
| 2007-03-31 | $1.52B | $6.27B | 24.21% |
| 2006-12-31 | $1.40B | $6.06B | 23.07% |
| 2006-09-30 | $1.26B | $5.56B | 22.60% |
| 2006-06-30 | $1.00B | $5.07B | 19.70% |
| 2006-03-31 | $1.01B | $4.66B | 21.73% |
| 2005-12-31 | $0.96B | $4.22B | 22.63% |
| 2005-09-30 | $0.77B | $4.08B | 18.89% |
| 2005-06-30 | $0.93B | $3.90B | 23.83% |
| 2005-03-31 | $0.44B | $3.68B | 11.92% |
| 2004-12-31 | $0.39B | $3.56B | 10.91% |
| 2004-09-30 | $0.64B | $3.48B | 18.53% |
| 2004-06-30 | $0.62B | $3.42B | 18.16% |
| 2004-03-31 | $0.83B | $3.37B | 24.53% |
| 2003-12-31 | $0.87B | $3.23B | 26.84% |
| 2003-09-30 | $0.51B | $3.12B | 16.24% |
| 2003-06-30 | $0.57B | $3.34B | 17.03% |
| 2003-03-31 | $0.73B | $3.59B | 20.46% |
| 2002-12-31 | $0.77B | $3.83B | 20.14% |
| 2002-09-30 | $0.69B | $4.03B | 17.21% |
| 2002-06-30 | $0.65B | $3.84B | 16.94% |
| 2002-03-31 | $0.70B | $3.67B | 19.14% |
| 2001-12-31 | $0.61B | $3.50B | 17.48% |
| 2001-09-30 | $0.96B | $3.23B | 29.66% |
| 2001-06-30 | $0.92B | $3.07B | 29.87% |
| 2001-03-31 | $0.71B | $2.93B | 24.26% |
| 2000-12-31 | $0.74B | $2.79B | 26.49% |
| 2000-09-30 | $0.70B | $2.97B | 23.57% |
| 2000-06-30 | $0.68B | $3.05B | 22.23% |
| 2000-03-31 | $0.82B | $3.14B | 26.11% |
| 1999-12-31 | $0.78B | $3.17B | 24.55% |
| 1999-09-30 | $0.76B | $3.05B | 25.01% |
| 1999-06-30 | $0.43B | $2.90B | 14.75% |
| 1999-03-31 | $0.30B | $2.82B | 10.72% |
| 1998-12-31 | $0.32B | $2.78B | 11.34% |
| 1998-09-30 | $0.29B | $2.72B | 10.47% |
| 1998-06-30 | $0.57B | $2.66B | 21.32% |
| 1998-03-31 | $0.67B | $2.56B | 26.08% |
| 1997-12-31 | $0.30B | $2.47B | 12.17% |
| 1997-09-30 | $0.28B | $2.44B | 11.32% |
| 1997-06-30 | $0.29B | $2.46B | 11.93% |
| 1997-03-31 | $0.31B | $2.80B | 11.00% |
| 1996-12-31 | $0.67B | $3.15B | 21.23% |
| 1996-09-30 | $0.69B | $3.45B | 19.91% |
| 1996-06-30 | $0.67B | $3.70B | 18.22% |
| 1996-03-31 | $0.66B | $3.67B | 18.03% |
| 1995-12-31 | $0.65B | $3.66B | 17.73% |
| 1995-09-30 | $0.65B | $3.66B | 17.61% |
| 1995-06-30 | $0.63B | $3.69B | 17.10% |
| 1995-03-31 | $0.61B | $3.64B | 16.75% |
| 1994-12-31 | $0.60B | $3.54B | 16.85% |
| 1994-09-30 | $-0.17B | $3.40B | -4.94% |
| 1994-06-30 | $-0.18B | $3.46B | -5.27% |
| 1994-03-31 | $-0.19B | $3.54B | -5.48% |
| 1993-12-31 | $-0.20B | $3.67B | -5.40% |
| 1993-09-30 | $0.58B | $3.82B | 15.13% |
| 1993-06-30 | $0.61B | $3.94B | 15.56% |
| 1993-03-31 | $0.61B | $4.01B | 15.07% |
| 1992-12-31 | $0.61B | $4.09B | 14.98% |
| 1992-09-30 | $0.61B | $4.23B | 14.47% |
| 1992-06-30 | $0.60B | $4.22B | 14.19% |
| 1992-03-31 | $0.62B | $4.22B | 14.56% |
| 1991-12-31 | $0.59B | $4.25B | 13.91% |
| 1991-09-30 | $0.59B | $4.18B | 14.00% |
| 1991-06-30 | $0.56B | $4.09B | 13.78% |
| 1991-03-31 | $0.53B | $4.02B | 13.27% |
| 1990-12-31 | $0.04B | $3.94B | 1.02% |
| 1990-09-30 | $0.00B | $3.98B | 0.03% |
| 1990-06-30 | $-0.03B | $4.02B | -0.80% |
| 1990-03-31 | $-0.04B | $4.06B | -0.94% |
| 1989-12-31 | $0.45B | $4.10B | 10.87% |
| 1989-06-30 | $0.29B | $4.00B | 7.26% |
| 1989-03-31 | $0.28B | $3.95B | 7.02% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $8.854B | $11.244B |
| Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |